articleTop 1% cited

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Annals of Oncology · 2012 · Vol. 24(1) · pp. 152–160

Halfdan Sørbye✉(Haukeland University Hospital)Staffan Welin(Uppsala University)Seppo W. Langer(University of Copenhagen)Lene Weber Vestermark(Odense University Hospital)Nanna Holt Jessen(Aarhus University Hospital)Pia Österlund(Helsinki University Hospital)Svein Dueland(Oslo University Hospital)Eva Hofsli(St Olav's University Hospital)Marianne G. Guren(Oslo University Hospital)Katarina Öhrling(Karolinska University Hospital)Elke Birkemeyer(Stavanger University Hospital)Espen Thiis‐Evensen(Oslo University Hospital)Matteo Biagini(Odense University Hospital)Henning Grønbæk(Aarhus University Hospital)Leena‐Maija Soveri(Helsinki University Hospital)Ingrid Holst OlsenBirgitte Federspiel(University of Copenhagen)J Assmus(Haukeland University Hospital)Eva Tiensuu Janson(Uppsala University)Ulrich Knigge

View via DOI Publisher page

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Pancreatic and Hepatic Oncology ResearchMedicineNeuroendocrine carcinomaInternal medicineOncologyCarcinomaNeuroendocrine tumors

MeSH terms

AgedAged, 80 and overFemaleGastrointestinal NeoplasmsHumansMaleMiddle AgedPrognosisROC CurveSurvival AnalysisCarcinoma, NeuroendocrineHistory, 16th Century

Citations

1,008

FWCI

22.18

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms